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IreadwithinterestthetimelyarticlebyRasoliandcolleagues,
who reviewed the literature on the eﬃcacy of antioxidant
vitamins in the management of atrial ﬁbrillation (AF) [1].
Those authors emphasized an important clinical issue:
despite considerable evidence of the role of oxidative stress
in the pathogenesis of AF, antioxidant vitamins have not
been shown to exert an impressive antiarrhythmic eﬀect in
clinical trials. In addition to the authors’ explanations for
that ﬁnding, it may also be possible that treatment with a
generalreactiveoxygenspecies(ROS)scavengerisineﬀective,
regardless of the type or potency of the scavenger. This may
occurbecauseROS area widerange of(usually)highly active
molecules that, when they are formed, react with proteins
and lipids in their immediate vicinity. Therefore, ROS scav-
engers cannot prevent the eﬀects of already formed ROS
molecules. In addition, those scavengers may not neutralize
all forms of ROS molecules, some of which may remain to
exert a downstream arrhythmic eﬀect.
Inhibiting the major source of excess ROS is a diﬀerent
therapeutic approach that may prove eﬀective in the man-
agement of various types of arrhythmia. The major sources
of cardiac ROS are nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase, the mitochondria electron trans-
port chain, and uncoupled endothelial nitric oxide synthase.
Those sources of ROS are interrelated, and the activation of
one may result in the increased production of ROS by other
sources, particularly by mitochondria (ROS-induced-ROS
release) [2]. Under diﬀerent conditions and for each type of
AF, one or some of the main sources of ROS may play the
central role in the genesis of arrhythmia. It has been shown
thatNADPHoxidaseisupregulatedininitialstagesofAF[3],
and therefore, NADPH oxidase inhibitors may be eﬀective in
the management of new onset AF and postoperative AF [4].
However, the upregulation of NADPH oxidase was found to
be transient and only in initial stages of AF, and therefore, its
inhibitionmaynotbeaneﬀectivetherapeuticstrategyforthe
management of chronic AF [3]. Because a considerable por-
tion of a cardiomyocyte is occupied by mitochondria [5]a n d
because mitochondria plays a central role in ROS-induced-
ROSrelease,mitochondria-targetedantioxidanttherapymay
prove to be the most eﬀective antioxidant therapy for man-
agement of chronic AF. We have recently observed the im-
pressive antiarrhythmic eﬀect of Mito-TEMPO, a mitochon-
dria-targeted antioxidant, in the prevention of ventricular
arrhythmias in a mouse model of angiotensin-II activation
[6]. Thus, it could be hypothesized that mitochondria-
targeted antioxidants can eﬀectively prevent chronic AF.
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